Turkish Ministry of Health Allows Public Reimbursement for CytoSorb®
of Treatment costs with CytoSorb® now covered by the public sector turkey
Princeton, New Jersey, August 23, 2022 /PR Newswire/ — Sight Sorbent Co., Ltd. (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care units and cardiac surgery using blood purification with proprietary polymer adsorption technology, announced that the Turkish Ministry of Health has approved national reimbursement for CytoSorb® Did. It is currently a catalog product that has been refunded by the State Supply Authority. turkey (DMO) portal, which can be purchased directly by hospitals and doctors without restrictions.
Doctor Christian SteinerCytoSorbents Executive Vice President of Sales and Marketing said: turkey, an estimated 140,000 patients are treated in the ICU for severe sepsis or infection-related septic shock and are at high risk of death. , many of which are medical tourists undergoing treatment in private hospitals. In addition, there are many other critically ill patients suffering from other life-threatening conditions such as acute lung or liver failure, trauma, etc., for whom CytoSorb can be used to control lethal inflammation and provide organ support. This reimbursement will allow more patients to access her breakthrough CytoSorb therapy, which adds a new dimension to blood purification. ”
Dr. Steiner applauded the strategic collaboration with new distribution partner Bıçakcılar Medical Devices. “Our partnership with Bıçakcılar has helped us win national reimbursements and include his CytoSorb® in the DMO’s healthcare catalog. We look forward to expanding the Turkish market.”
Bıçakcılar Medical Devices is a leading manufacturer of disposable medical products and OR solutions. turkeyThe company was founded in 1959. Over the years, the Bıçakcılar brand has established a tradition of widespread acceptance and continued reliability and customer satisfaction.
Doctor Suail El HakimBıçakcılar’s Chief Executive Officer, Highlighted the Key Collaboration between the Companies towards Patient-Centric Solutions Critical to Improving Clinical Outcomes for Critically Ill Patients turkey from. “We believe that everyone deserves affordable and effective health care. Especially in critical care medicine, with the help of large-scale production facilities, we are able to provide the most effective treatments. At the same time, we are working to have a direct impact on healthcare.With CytoSorbents, we have found one of the most innovative partners to help us achieve this, and I It gives us the opportunity to further revitalize our approach.”
turkey It provides universal healthcare to about 95% of its 84 million people, comparable in size to Germany. There are over 1,500 hospitals, approximately 62% are public or university hospitals and 38% are private. turkey It has an extensive network of intensive care units and has the highest number of ICU beds per 100,000 population among developed countries, about 46 compared to 29 in the United States and 39 in the United States. Germanyfor example. turkey It is also a hub for medical tourism in the region, attracting 1.7 million patients from abroad. turkey Annually, especially for cardiovascular, thoracic, plastic surgery, orthopedic and other surgical procedures.
About Bıçakcılar Medical
Bıçakcılar Medical is a company with a history of 60 years and has created many “firsts”. turkey where I was born. Over the years, Bıçakcılar Medical has expanded globally, providing essential healthcare products that have saved lives around the world. From medical disposables to OR solutions, we stand out with two unique attributes. Error-free quality control and unique expert after-sales service add exceptional durability to medical devices. Focusing on the ‘patient’ is just one of the reasons why so many domestic and international customers have partnered with the company over his 20+ years. With over 800 employees and many business partners, Bıçakcılar serves its customers by manufacturing and providing innovative, reliable and environmentally friendly medical devices. Bıçakcılar is committed to saving lives while benefiting society and the environment.
CytoSorbents Corporation is a leader in treating life-threatening conditions in critical care and cardiac surgery with blood purification. His flagship product, CytoSorb®, is approved in the European Union and sold in over 70 countries worldwide. This is an extracorporeal cytokine designed to reduce the “cytokine storm” or “cytokine release syndrome” that occurs in common critical illnesses and can lead to massive inflammation, organ failure and patient death. Adsorbent. These diseases can carry a very high risk of death, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to postoperative complications such as multi-organ failure.Current June 30, 2022, with over 179,000 CytoSorb devices in cumulative use worldwide. CytoSorb was first launched in the European Union under his CE mark as the first in vitro cytokine adsorbent. Additional CE mark extensions were granted for bilirubin and myoglobin ablation in clinical conditions such as liver disease and trauma, and for ticagrelor and rivaroxaban ablation during cardiothoracic surgery, respectively. CytoSorb has also received emergency FDA approval. usa For use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure. Based on the same polymer technology as CytoSorb, the DrugSorb™-ATR antithrombectomy system has FDA breakthrough device designation for removing ticagrelor and the direct oral anticoagulants (DOACs) apixaban and rivaroxaban in the cardiopulmonary bypass circuit. also received FDA Breakthrough Device designation. Emergency cardiothoracic procedure. The company has initiated two of his pivotal FDA-approved studies to support marketing approval of DrugSorb-ATR in the United States. First, randomization of 120 patients at 30 centers to assess whether intraoperative use of DrugSorb-ATR can reduce perioperative bleeding risk in Ticagrelor patients undergoing cardiothoracic surgery. Comparative STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) trial. The second study Star D Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants Intraoperative use of DrugSorb-ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery who are taking direct oral anticoagulants such as apixaban and rivaroxaban. Randomized controlled trial of 120 patients at 30 centers evaluating .
CytoSorbents’ purification technology is based on highly porous, biocompatible polymeric beads that can actively remove toxic substances from blood and other bodily fluids through pore entrapment and surface adsorption. Our technology is $39.5 million DARPA, U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), undiluted grants, contracts, and other funding from the U.S. Army, U.S. Air Force, U.S. Specialty Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), etc. Based on this unique blood purification technology, the company is protected by numerous issued U.S. and international patents and registered trademarks, as well as several pending patent applications such as ECOS-300CY®, CytoSorb-XL™ and HemoDefend- has a number of commercial and developmental products. RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, etc.For more information, visit the company’s websites www.cytosorbents.com and www.cytosorb.com, or follow us on Facebook and www.cytosorbents.com. twitter.
Forward-Looking Statements
This press release contains forward-looking statements within the safe harbor of the Private Securities Litigation Reform Act of 1995.business, expectations about the future impact of COVID-19, or ongoing disputes Russia When Ukraine, statements and claims, not historical facts, generally “could”, “should”, “could”, “expect”, “plan”, “anticipate” , identified by the use of words such as “believe”. “forecast”, “prediction”, “probability”, “continuation” and similar terms; Although the forward-looking statements in this press release reflect management’s current beliefs and expectations, actual results, events and performance may differ materially from the forward-looking statements. Please be careful. Factors that could cause or contribute to such differences include, but are not limited to, the risks disclosed in our Annual Report on Form 10-K filed with the SEC. not. March 10, 2022, quarterly reports on Form 10-Q, press releases and other communications to stockholders that we issue from time to time to inform our stakeholders of risks and factors that may affect our business. You are cautioned not to place undue reliance on such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by federal securities laws.
Click to follow us on Facebook. twitter
US company contact:
Amy Vogel
305 College Road East
Princeton, New Jersey 08540
+1 (732) 329-8885
[email protected]
European company contact:
Josephine Krause
+49 30 765 84 66 23
[email protected]
US PR:
Eric Kim
rubenstein public relations
212-805-3052
[email protected]
European PR:
Marcus Schult
componist
+49 69 13823 ext.960
+49 172 4238938
[email protected]
Source: CytoSorbents Corporation
